Material and in kind contributions by GLADEL members have been key to conceptualize, develop and sustain the GLADEL cohort.

In 2000, PANLAR provided funding to adapt the ARTHROS database and develop the original GLADEL cohort.

In 2007 an unrestricted educational grant from GlaxoSmithKline Pharmaceutical company (GSK) allowed the original centers to update the database.

Between 2016 and 2018 GLADEL, as the PANLAR Lupus study group, developed the PANLAR-GLADEL guidelines for lupus in LatinAmerica. This effort was supported with a unrestricted educational grants from GSK and UCB.

ILAR and GSK provided financial support to Emory University, which in partnership with GLADEL has developed and implemented an educational program for patients with lupus in Latin America entitled: “Hablemos de Lupus” / “Falando de Lupus”. Additional funding was provided by PANLAR to GLADEL to sustain the program.

 

More recently, Janssen Pharmaceuticals, Inc. has provided funding to study the impact of remission and low disease activity on the rate of hospitalization of the GLADEL cohort.